CY1108417T1 - Συνεργατικη αντιβακτηριακη και διαμορφωση μιας μεθοδου κανει το ιδιο - Google Patents

Συνεργατικη αντιβακτηριακη και διαμορφωση μιας μεθοδου κανει το ιδιο

Info

Publication number
CY1108417T1
CY1108417T1 CY20081101143T CY081101143T CY1108417T1 CY 1108417 T1 CY1108417 T1 CY 1108417T1 CY 20081101143 T CY20081101143 T CY 20081101143T CY 081101143 T CY081101143 T CY 081101143T CY 1108417 T1 CY1108417 T1 CY 1108417T1
Authority
CY
Cyprus
Prior art keywords
same
bacteria
construction
method makes
cooperative anti
Prior art date
Application number
CY20081101143T
Other languages
English (en)
Inventor
Sanjeev Khandelwal
Original Assignee
Sanjeev Khandelwal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanjeev Khandelwal filed Critical Sanjeev Khandelwal
Publication of CY1108417T1 publication Critical patent/CY1108417T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Συνέργιες σύνθεσης αντιβακτηριακή και μία μέθοδος δημιουργίας τον ίδιο προσωπικά. Η σύνθεση περιέχει Cefixime Τριενυδρο + Κλοξακιλίνη νάτριο + Lactobacillus sporogener σπόρια. Η Κλοξακιλίνη νάτριο είναι σε δύο μορφές σε μια σταθερή θέση και την άμεση απελευθέρωση μορφή. Ένα φάρμακο που παρέχει το σύστημα διανομής για τη διατύπωση.
CY20081101143T 2004-02-16 2008-10-15 Συνεργατικη αντιβακτηριακη και διαμορφωση μιας μεθοδου κανει το ιδιο CY1108417T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178MU2004 2004-02-16
IN258MU2004 2004-03-03
EP05250879A EP1566176B1 (en) 2004-02-16 2005-02-16 Synergistic antibacterial formulation and a method of making the same

Publications (1)

Publication Number Publication Date
CY1108417T1 true CY1108417T1 (el) 2014-04-09

Family

ID=34712743

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101143T CY1108417T1 (el) 2004-02-16 2008-10-15 Συνεργατικη αντιβακτηριακη και διαμορφωση μιας μεθοδου κανει το ιδιο

Country Status (5)

Country Link
US (1) US7632520B2 (el)
EP (1) EP1566176B1 (el)
AT (1) ATE401074T1 (el)
CY (1) CY1108417T1 (el)
DE (1) DE602005008122D1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
WO2013109229A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Tablet formulations comprising cefixime as active agent
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
CN110917220A (zh) * 2013-02-04 2020-03-27 赛里斯治疗公司 治疗组合物及其使用方法
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc MICROBIAL COMPOSITIONS AND ASSOCIATED METHODS BASED ON A NETWORK
CN116370507A (zh) 2013-11-25 2023-07-04 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP2020530840A (ja) 2017-08-14 2020-10-29 セレス セラピューティクス インコーポレイテッド 胆汁うっ滞性疾患を治療するための組成物及び方法
CN115025066B (zh) * 2021-05-25 2023-05-16 重庆市畜牧科学院 一种质量稳定的抗仔猪腹泻中药缓释颗粒的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6483025A (en) * 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
IN183097B (el) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
AU747549B2 (en) * 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof

Also Published As

Publication number Publication date
US7632520B2 (en) 2009-12-15
DE602005008122D1 (de) 2008-08-28
US20050181051A1 (en) 2005-08-18
EP1566176B1 (en) 2008-07-16
ATE401074T1 (de) 2008-08-15
EP1566176A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
CY1108417T1 (el) Συνεργατικη αντιβακτηριακη και διαμορφωση μιας μεθοδου κανει το ιδιο
CY1118179T1 (el) Φαρμακευτικη συνθεση
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
CU23367A3 (es) Formulación de moxifloxacino con sal común
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
ATE429923T1 (de) Botulinum-toxin-formulierungen zur oralen verabreichung
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ATE297723T1 (de) Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
CL2009001874A1 (es) Uso de bacillus subtilis qst713 nrrl b-21661 para formular una composición probiótica para un animal; y composición probiotica de bacillus subtilis qst713 nrrl b-21661.
MY144318A (en) Methods of treating hiv infection.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CY1112167T1 (el) Νεα χρηση αντιβιοτικων κινολονης
WO2006034001A3 (en) Methods of treating hiv infection
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
BRPI0916885B8 (pt) composição farmacêutica
WO2008057196A3 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
IL172096A0 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
CL2009001330A1 (es) Compuestos derivados de ciano-3-oxoisoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno de dolor.